MCED (methylation-based multicancer early detection) Test Can Aid Cancer Diagnosis in Symptomatic Patients
Test could diagnose cancer in patients with non-specific symptoms: A study in the journal The Lancet Oncology found that a methylation-based multicancer early detection test demonstrated a 98.4% specificity and 66.3% sensitivity, with its sensitivity increasing with the increase of cancer stage and age. “MCED test results can help assess the risk that a symptom is due to cancer, providing a means for primary care physicians to decide whom to urgently investigate,” researchers wrote.